Press Room

Press Release / Jun 06, 2011

OSHA renews Hovione’s VPP STAR Certification

Top health and safety standards recognized

Loures, Portugal, June 6th, 2011 - Hovione announced today that its Technology Transfer Centre in New Jersey, USA, has achieved renewed membership in the prestigious "Star" Voluntary Protection Program (VPP) of the U.S. Department of Labor's Occupational Safety and Health Administration (OSHA). In communicating this renewal Robert D. Kulick, Regional Administrator of OSHA, indicated: “VPP participants serve as models for other employers and workers by operating excellent safety and health management programs. Achieving a level of worker protection that goes beyond compliance with government regulations is commendable”.

Being a Star participant in the Voluntary Protection Program means that the site is removed from the roster of OSHA inspections and that it opens its doors to others that may want to learn from the site’s practices.

“Hovione’s strategy is to stay ahead of requirements in every area of compliance – we do this because we have a genuine quality culture, we adopt best practices and we aim high. Quality and GMP compliance, health, safety and the environment – all rank high in our priorities. Our compliance record is something we are proud of. I also believe this gives comfort to our customers that we are the right home for their products” said Guy Villax, Chief Executive.

Hovione is a leading contract manufacturer that stands behind at least one NDA approval every year. In 2010 Hovione made clinical trial materials for over 60 different compounds, and supplied over 30 commercial APIs made in its sites.

About Hovione

Hovione is an international company with over 50 years’ experience in Active Pharmaceutical Ingredient development and compliant manufacture. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For more information about Hovione, please visit the Hovione site at www.hovione.com  or contact: 

Marketing & Communication, Isabel Pina, + 351 21 982 9362, e-mail: ipina@hovione.com .

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026